Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
|Slideshows|August 10, 2018
5 Reports on Depression
Author(s)James Murrough, MD, PhD
This special collection provides new insights on major aspects of depression: psychopharmacology, therapeutic interventions, major depressive episodes, biomarkers, and pseudobulbar affect.
Advertisement
Advertisement
Related to this article
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
4
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
5